Exact Sciences Gets Medicare Approval for Colorectal Blood Test

Exact Sciences gets Medicare approval for colorectal blood test

The Oncodetect test is designed for use in patients with stage II, III and some stage IV colorectal cancer.

Exact Sciences' Oncodetect test receives Medicare coverage

Exact Sciences gets Medicare coverage for its colorectal cancer test

Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer

MADISON, Wis.--(BUSINESS WIRE)--Jul 9, 2025-

#Revolutionizing Colorectal Cancer Care Medicare Coverage for Exact Sciences MRD Test Opens New Avenues

In a significant advancement for colorectal cancer (CRC) patients, Exact Sciences Corp., a leading player in cancer diagnostics, recently announced that its Oncodetect molecular residual disease (MRD) test will now be covered by Medicare. This decision, made through the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostic Services Program (MolDX), marks a crucial development for patients with stage II, III, and resectable stage IV…

MRD Testing: Guidelines and Clinical Decision-Making in Treatment-Naive CLL

Panelist discusses how minimal residual disease testing serves as an important tool for guiding treatment decisions in fixed-duration therapy, though standardization of testing methods and interpretation remains challenging in real-world practice.